Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 15/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SELL | P14151 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19491946 | 0.93 | SELE (0.50) | SELEALDH1A1THRBSELP | |
| SCHEMBL19491871 | 0.90 | SELE (0.49) | SELEALDH1A1THRBMAPK1SELL | |
| SCHEMBL21992170 | 0.87 | SELE (0.46) | SELEALDH1A1THRBMAPK1SELL | |
| SCHEMBL19479261 | 0.85 | SELE (0.45) | SELEALDH1A1THRBMAPK1SELL | |
| SCHEMBL19479265 | 0.84 | SELE (0.44) | SELEALDH1A1THRBMAPK1SELL | |
| SCHEMBL24489392 | 0.83 | SELE (0.49) | SELEALDH1A1THRBMAPK1SELL | |
| SCHEMBL25446620 | 0.83 | SELE (0.48) | SELEALDH1A1THRBMAPK1 | |
| SCHEMBL24489376 | 0.82 | SELE (0.42) | SELEALDH1A1THRBMAPK1SELL | |
| SCHEMBL21991817 | 0.81 | SELE (0.50) | SELEALDH1A1THRBSELL | |
| SCHEMBL19479236 | 0.80 | SELE (0.44) | SELEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796745-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170296566-A9 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | GLYCOMIMETICS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170296566-A9 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | SELE, SELP, SELPLG | SELE 1/4885ALDH1A1 636/4885THRB 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.